UCB (ENXTBR:UCB) - Aandelenkoers, Nieuws & Analyse

UCB Overzicht aandelen

UCB SA, een biofarmaceutisch bedrijf, ontwikkelt wereldwijd producten en oplossingen voor mensen met neurologische en immunologische ziekten.

Over het bedrijf

UCB fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	1/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 66.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 35.52% per jaar groeien

Risicoanalyse

Winstmarges (4.4%) zijn lager dan vorig jaar (6.5%)

UCB SA Concurrenten

Financière de Tubize

ENXTBR:TUB

€6.4b

Jiangsu Hengrui Medicine

SHSE:600276

CN¥309.5b

Takeda Pharmaceutical

TSE:4502

JP¥6.8t

Otsuka Holdings

TSE:4578

JP¥5.1t

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor UCB
Historische aandelenkoersen
Huidige aandelenkoers	€179.45
52 Week Hoogtepunt	€183.80
52 Week Laag	€65.40
Bèta	0.36
11 maand verandering	7.84%
3 maanden verandering	17.90%
1 Jaar Verandering	164.21%
33 jaar verandering	71.07%
5 jaar verandering	146.16%
Verandering sinds IPO	58,709.84%

Recent nieuws en updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Recent updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Rendement voor aandeelhouders

	UCB	BE Pharmaceuticals	BE Markt
7D	-0.1%	-3.8%	-2.6%
1Y	164.2%	8.2%	7.9%

Rendement versus industrie: UCB overtrof de Belgian Pharmaceuticals industrie, die het afgelopen jaar een rendement 8.2 % opleverde.

Rendement versus markt: UCB overtrof de Belgian markt, die het afgelopen jaar een rendement opleverde van 7.9 %.

Prijsvolatiliteit

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.3%
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	3.3%
10% most volatile stocks in BE Market	6.5%
10% least volatile stocks in BE Market	2.2%

Stabiele aandelenkoers: UCB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van UCB is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1925	9,000	Jean-Christophe Tellier	www.ucb.com

UCB SA, een biofarmaceutisch bedrijf, ontwikkelt wereldwijd producten en oplossingen voor mensen met neurologische en immunologische ziekten. De belangrijkste producten van het bedrijf zijn Cimzia voor inflammatoire TNF-gemedieerde ziekten, evenals ankyloserende spondylitis, axiale spondyloartritis, de ziekte van Crohn, niet-radiografische axiale spondyloartritis, plaque psoriasis, psoriatische artritis en reumatoïde artritis; Vimpat, Keppra en Briviact voor epilepsie; Neupro voor de ziekte van Parkinson en het rustelozebenensyndroom; Nayzilam, een neusspray als reddingsbehandeling voor epilepsieaanvalclusters; en Zyrtec en Xyzal voor allergieën. Het bedrijf biedt ook Evenity voor de behandeling van osteoporose bij postmenopauzale vrouwen; Bimzelx voor de behandeling van plaque psoriasis, psoriatische artritis en axiale spondyloartritis; en Fintepla voor de behandeling van het Dravetsyndroom.

UCB SA Samenvatting

Hoe verhouden de winst en inkomsten van UCB zich tot de beurswaarde?
UCB fundamentele statistieken
Marktkapitalisatie	€34.05b
Inkomsten(TTM)	€240.00m
Inkomsten(TTM)	€5.45b

141.9x

Koers/Winstverhouding

6.2x

P/S-verhouding

Is UCB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
UCB resultatenrekening (TTM)
Inkomsten	€5.45b
Kosten van inkomsten	€1.76b
Brutowinst	€3.70b
Overige uitgaven	€3.46b
Inkomsten	€240.00m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Feb 27, 2025

Winst per aandeel (EPS)	1.27
Brutomarge	67.80%
Nettowinstmarge	4.40%
Schuld/Eigen Vermogen Verhouding	31.8%

Hoe presteerde UCB op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.8%

Huidig dividendrendement

108%

Uitbetalingsratio

UCB Overzicht aandelen

Beloningen

Risicoanalyse

UCB SA Concurrenten

ENXTBR:TUB

€6.4b

SHSE:600276

CN¥309.5b

TSE:4502

JP¥6.8t

TSE:4578

JP¥5.1t

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Recent updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released